(Q34452166)

2 August 2017

1 reference

title

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development (English)

1 reference

2 August 2017

1 reference

1 reference

Kolvenbag GJ

1

1 reference

2 August 2017

Blackledge GR

series ordinal

2

1 reference

2 August 2017

Gotting-Smith K

series ordinal

3

1 reference

2 August 2017

publication date

1 January 1998

1 reference

2 August 2017

1 reference

2 August 2017

volume

34

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

61-72

1 reference

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Phase II studies on prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Worldwide activity and safety of bicalutamide: a summary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Efficacy and tolerability of Casodex in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

21 January 2018

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Casodex--mechanisms of action and opportunities for usage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N

10.1002/(SICI)1097-0045(19980101)34:1<61::AID-PROS8>3.0.CO;2-N

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference